Using the Multiple Attribute Method for Process Development and Quality Control
More manufacturers are embracing MAM, which simplifies biopharmaceutical product quality testing, and facilitates the measurement and monitoring of critical quality attributes.
In this interview with Biopharm International, Richard Rogers, principal scientist at Just Biotherapeutics and formerly a member of the Amgen team that developed and proved the concept behind MAM, describes the story behind the method, how it is moving from quality control testing into drug development, and how it is helping to guide new product and software development.
Read this article in BioPharm International's Outsourcing Resources 2019 eBook.
Article Details
BioPharm International
eBook: Outsourcing Resources 2019
April 2019
Pages: 12–14
Citation
When referring to this article, please cite it as A. Shanley, "Using the Multiple Attribute Method for Process Development and Quality Control," BioPharm International's Outsourcing Resources eBook (April 2019).
FDA Approves Pfizer Combination Regimen for Treating R/R Diffuse Large B-Cell Lymphoma
February 14th 2025The approval of an ADCETRIS combination regimen is based on positive data from a Phase III trial where the combination regimen demonstrated a clinically meaningful reduction in the risk of death.
